Assisted reproductive technology (ART) is the most efficient therapy for infertility. There are around 2,000,000 in vitro fertilization (IVF) cycles per year worldwide. In IVF, the key to success is to select a high developmental potential embryo for transfer.
Our product is a cloud service platform consisting of zygote morphokinetic parameters segmentation algorithm and early blastocyst formation prediction model. We aim to serve the Assisted reproductive technology (ART) centres by predicting blastocyst formation potential and implantation potential of the embryo. And we serve the mid-stream research institutions and companies by solving the technical bottleneck with our service.
The cloud service platform is to assist IVF doctors and embryologists in selecting high developmental potential embryos, and we plan to perform trial runs with our collaborated IVF centres to test the performance of the cloud service platform.
Our unique and first of ever technology in the field can provide earlier, and precise embryo developmental prediction based on our intellectual property ‘method and apparatus for segmenting cellular image’ and technology ‘zygote morphokinetic prediction model’ (ZMP model). With our service, IVF practitioners can be more confident to choose an appropriate embryo transfer plan as well as take action for better clinical decision in advance.